**Supplemental Figure 3**

**A**

![Image A](https://example.com/image1.png)

**B**

![Image B](https://example.com/image2.png)

**C**

![Image C](https://example.com/image3.png)

**D**

![Image D](https://example.com/image4.png)
Supplemental Figure 3 | Verification of depletions

A, Representative plots and bar chart for CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup> TAMs in MOC2 tumors harvested 16 days post-RT with RT or RT + anti-CSF1R treatment. B, Representative plots and bar chart for CD45<sup>+</sup>CD11b<sup>+</sup>Ly-6C<sup>hi</sup>Ly-6G<sup>−</sup> M-MDSCs or CD45<sup>+</sup>CD11b<sup>+</sup>Ly-6C<sup>mid</sup>Ly-6G<sup>+</sup> PMN-MDSCs in blood collected from live C57Bl/6 mice 1 day pre-implantation with anti-Gr-1 treatment versus untreated controls. C, Representative plots and bar chart for CD45<sup>+</sup>CD3<sup>+</sup>CD4<sup>+</sup> T cells or CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup> T cells in blood collected from live mice bearing MOC2 tumors 14 days post-RT with RT or RT + anti-CD25 + anti-CD137 + anti-CD4 + anti-CD8 treatment. D, Representative plots and bar chart for CD45<sup>+</sup>CD4<sup>+</sup>Foxp3<sup>+</sup> Tregs in blood collected from live mice bearing MOC2 tumors 19 days post-implantation with DT treatment vs untreated controls.